Cogent Biosciences, Inc.
COGT
Classificação em ações
#3284
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Preço da ação
$31.17
Valor de mercado
$5.41B
Variação (1 dia)
3.87%
Variação (1 ano)
92.17%
País
US
Negociar Cogent Biosciences, Inc. (COGT)
Categoria
Healthcare
Rácio P/S de Cogent Biosciences, Inc. (COGT)
Rácio P/S em October 2026 TTM: 0.00
De acordo com os relatórios financeiros mais recentes e o preço das ações da Cogent Biosciences, Inc., o rácio P/S atual (TTM) é 0.00. No final de 2023, o rácio P/S era 0.00.
Histórico do rácio P/S da Cogent Biosciences, Inc. de 2015 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | 15.81 | 1,520.90% |
| 2019 | 0.98 | -91.33% |
| 2018 | 11.25 | -71.38% |
| 2017 | 39.32 | -3.98% |
| 2016 | 40.95 | -53.01% |
| 2015 | 87.14 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
